Terazosin

Terazosin: May be taken with or without food.

History of micturition syncope.

Patient with heart failure, pulmonary oedema due to mitral or aortic valve stenosis. Patient undergoing cataract surgery. Concomitant use with other antihypertensive agents (e.g. verapamil). Hepatic impairment. Elderly. Pregnancy and lactation. Patient Counselling This drug may cause dizziness and drowsiness, if affected, do not drive or operate machinery. Monitoring Parameters Monitor blood pressure (standing and sitting or supine position), particularly 2-4 hours after the initial dose and thereafter. Observe for dizziness, palpitations, somnolence, and impotence during initiation of therapy and regularly. In patients with benign prostatic hyperplasia (BPH): Rule out the presence of prostate carcinoma before initiating therapy; monitor the International Prostate Symptom Score (at baseline and 4-12 weeks after initiation of treatment) and urinalysis (at baseline).

Significant: Postural hypotension, syncope (particularly during the initial treatment); intraoperative floppy iris syndrome (during cataract surgery). Rarely, priapism. Blood and lymphatic system disorders: Thrombocytopenia. Cardiac disorders: Palpitations, tachycardia, arrhythmia, atrial fibrillation. Ear and labyrinth disorders: Vertigo, tinnitus. Eye disorders: Blurred vision, amblyopia, visual impairment, conjunctivitis. Gastrointestinal disorders: Nausea, vomiting, diarrhoea, constipation, abdominal pain, dry mouth, flatulence, dyspepsia. General disorders and administration site conditions: Asthenia, pyrexia, chest pain. Immune system disorders: Rarely, allergic reactions (including anaphylaxis). Investigations: Increased weight; decreased haematocrit, Hb, WBC count, total protein and blood albumin. Metabolism and nutrition disorders: Peripheral oedema, facial oedema. Musculoskeletal and connective tissue disorders: Pain in extremities, back pain, neck pain, shoulder pain, arthralgia, myalgia, gout, arthritis, joint disorders. Nervous system disorders: Dizziness, somnolence, headache, paraesthesia. Psychiatric disorders: Depression, nervousness, anxiety, insomnia. Renal and urinary disorders: UTI, urinary incontinence (primarily in postmenopausal women), urinary frequency. Reproductive system and breast disorders: Erectile dysfunction, decreased libido. Respiratory, thoracic and mediastinal disorders: Rhinitis, nasal congestion, sinusitis, cough, bronchitis, pharyngitis, dyspnoea, flu symptoms, cold symptoms, epistaxis. Skin and subcutaneous tissue disorders: Hyperhidrosis, rash, pruritus. Vascular disorders: Vasodilation.

Increased incidence of dizziness or other dizziness-related adverse events with ACE inhibitors (e.g. captopril) and diuretics. May increase the risk of hypotension with other antihypertensive agents (e.g. verapamil) and phosphodiesterase-5 inhibitors (e.g. sildenafil, tadalafil).

Drugs for Bladder & Prostate Disorders / Other Antihypertensives

G04CA03 - terazosin ; Belongs to the class of alpha-adrenoreceptor antagonists. Used in the treatment of benign prostatic hypertrophy.